Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu, +11

Circulation

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Paolo A. Ascierto, David R. Minor, Antoni Ribas, +17

Journal of Clinical Oncology

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Chantal Mathieu, Paresh Dandona, Pieter Gillard, +10

Diabetes Care

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Rosalie A. Scholtes, Marcel H.A. Muskiet, Michiel J.B. van Baar, +7

Diabetes Care

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

Ivy Song, Julie Borland, Niki Arya, +2

The Journal of Clinical Pharmacology

NutritionNutrient BioavailabilityDolutegravir ExposureCalcium CarbonatePharmacology +11

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

Howard A. Burris, Charles W. Taylor, Suzanne F. Jones, +8

Clinical Cancer Research

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the <scp>DEPICT</scp> ‐2 study): 52‐week results from a randomized controlled trial

Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, +7

Diabetes Obesity and Metabolism

<scp>Long‐term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52‐week</scp> outcomes from the <scp>DEPICT</scp> ‐1 and ‐2 studies

Moshe Phillip, Chantal Mathieu, Marcus Lind, +11

Diabetes Obesity and Metabolism

Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A <i>Post Hoc</i> Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS)

Dave Singh, Fernando J. Martínez, John R. Hurst, +11

American Journal of Respiratory and Critical Care Medicine

Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study

Chantal Mathieu, Paresh Dandona, Pieter Gillard, +9

Diabetes

Diabetes—depict-2 StudyCardiometabolic RiskPharmacotherapyObesityMetabolic Syndrome +15